Oregon Psilocybin Entrepreneurs Navigate Business Requirements

As psilocybin businesses prepare to open under state law next year, entrepreneurs are looking to lawyers to help them navigate complex and challenging regulatory requirements. 

Awakn Navigates the Tough Market for Investment Capital

The drug development company inspires psychedelics experts, but struggles to raise funds for its ketamine-assisted therapies and addiction treatments.

Now Companies Can Buy Insurance To Cover Ketamine Therapy for Employees

Enthea will provide psychedelic health care benefits through employers, with plans to expand across 40 states.

Carey Turnbull Wears Many Hats as a Donor and Investor

The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it. 

What’s the Future of Eleusis Therapeutics After Acquisition by Beckley Psytech?

Eleusis’ IV form of psilocin will see clinical trials, but Eleusis-backed research into the anti-inflammatory properties of psychedelics is uncertain.

Eleusis Holdings Plans To Be Acquired By Beckley Psytech

The acquisition is the latest sign of stress among startups in the sector, which has seen valuations plummet.

Young Psychedelic Philanthropist Blazes Path for the Psychedelic Future

With the support of his family, Cody Swift has funded pivotal research into psychedelic therapies and the conservation of peyote and other Indigenous medicines. 

Can Psychedelics Treat Inflammation and Eye Disease? Eleusis Thinks So.

The company is betting that psychedelic medicines can promote physical as well as mental health. Can it convince investors?

Journey Colab Looks to Mescaline for Treating Alcohol Use Disorder

An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.

Numinus’s Acquisition of Novamind May Signal More Consolidation to Come

Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”